NCT00691015 · OUTCOME

Incidence of Chronic GVHD.

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant · Source last updated 2017-06-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: Within 2 years after PBSCT

Analysis population: All participants

Groups in this outcome

All Participants

All regimens were analyzed together.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Participants	47

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
All Participants	44.68	Not reported	30.17	59.88	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
30.17
upper Limit
59.88
value
44.68

denoms

counts
group Id
OG000
value
47
units
Participants

dispersion Type

95% Confidence Interval

groups

description
All regimens were analyzed together.
id
OG000
title
All Participants

param Type

NUMBER

population Description

All participants

reporting Status

POSTED

time Frame

Within 2 years after PBSCT

title

Incidence of Chronic GVHD.

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice